GLP-1类药物如Ozempic正在改变北美饮食习惯, GLP-1 drugs like Ozempic are reshaping North American eating habits, reducing fast-food spending and boosting demand for healthier options.

GLP-1类药物,如Ozempic和Wegovy,最初用于糖尿病,正通过减少食欲和减缓消化速度,推动北美饮食习惯发生重大变化。 GLP-1 drugs like Ozempic and Wegovy, originally for diabetes, are driving major shifts in eating habits across North America by reducing appetite and slowing digestion. 一项2024年的Kantar调查发现,42%的加拿大用户改变了他们的饮食习惯,34%的人吃得较少,30%的人选择了较小的部分。 A 2024 Kantar survey found 42% of Canadian users changed their eating habits, 34% ate less often, and 30% chose smaller portions. 在美国,快餐和有限服务餐馆的支出在使用第一年下降了8%,威胁着工业收入。 In the U.S., spending at fast-food and limited-service restaurants dropped 8% in the first year of use, threatening industry revenue. 许多用户现在更喜欢烤蛋白质、沙拉和低糖食品,减少经过加工的膳食。 Many users now prefer grilled proteins, salads, and lower-sugar foods, cutting back on processed meals. 随着对这些药物需求的增加,预计到2030年加拿大将达到三倍,快餐连锁店可能面临长期压力,除非它们适应消费者不断变化的行为。 As demand for these drugs grows, with projections of a tripling in Canada by 2030, fast-food chains may face lasting pressure unless they adapt to changing consumer behavior.